Comparative Pharmacology
Head-to-head clinical analysis: FENOGLIDE versus KYNAMRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENOGLIDE versus KYNAMRO.
FENOGLIDE vs KYNAMRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fenofibrate is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It increases lipolysis and elimination of triglyceride-rich particles from plasma, reduces hepatic production of VLDL, and increases HDL cholesterol.
Kynamro (mipomersen) is an antisense oligonucleotide that specifically binds to the mRNA of apolipoprotein B-100 (apoB-100), inhibiting its translation and reducing the production of apoB-100-containing lipoproteins, including LDL, VLDL, and Lp(a).
160 mg orally once daily, taken with or without food.
Kynamro (mipomersen) is administered subcutaneously at a dose of 200 mg once weekly.
None Documented
None Documented
The terminal elimination half-life of fenofibric acid is approximately 20 hours (range 15-25 hours). This long half-life allows once-daily dosing. Steady-state is reached within approximately 5 days.
Terminal elimination half-life is approximately 28-31 days (range 21-40 days) in patients with homozygous familial hypercholesterolemia, supporting weekly subcutaneous dosing.
Fenoglide (fenofibrate) is primarily excreted in urine as fenofibric acid and its glucuronide conjugate, accounting for approximately 60-70% of the dose. About 20-25% is eliminated in feces via biliary excretion. Renal excretion is the major route.
Primarily hepatobiliary elimination; less than 1% excreted unchanged in urine. Mipomersen is metabolized by endonucleases and exonucleases to shorter oligonucleotides, which are excreted in bile and feces.
Category C
Category C
Antilipemic
Antilipemic